logo
  

Ford Teams Up With Allego To Bring Ultra-Fast Charging Facilities For EV Customers In Europe

Auto giant, Ford Motor Company (F), Tuesday announced that it is collaborating with Allego N.V. (ALLG) to bring ultra-fast charging infrastructure to the company's EV customers across Europe.

The company stated that Allego's charging stations delivering 400 kW charging will be available at Ford dealerships.

Ford's European Manager, Charging & Energy Strategy and Go-to Market, Ford Model e, Oliver Adrian, says, "The new high-power charging stations will be included within the BlueOval Charge Network - Ford's public charging service - which enables drivers to access and pay for charging at more than 600,000 charging points³ in Europe. A key benefit for Ford customers will be the Plug & Charge technology at Allego charging stations - providing fast and secure charging without needing to use an app or RFID card."

Currently, Ford's stock is trading at $12.86, down 0.31 percent on the New York Stock Exchange.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Home improvement major Lowe's Companies, Inc. on Tuesday maintained its fiscal 2024 earnings and sales outlook after reporting weak results in its first quarter. However, the quarterly earnings per share were above market estimates. In pre-market activity on the NYSE, Lowe's shares were gaining around 3.1 percent... Veolia (VE) announced Tuesday that its consulting engineering and strategic and operational assistance division Seureca announced the acquisition of MRC Consultants and Transaction Advisers. The financial aspects of the deal are not revealed. The combination of MRC, an energy consulting firm in Spain... French drug major Sanofi is teaming with artificial intelligence or AI startup OpenAI, the developer of highly popular generative AI chatbot ChatGPT, as well as Formation Bio, an AI and tech-driven drug developer, to build AI-powered software to accelerate drug development and bring new medicines more efficiently.

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
Follow RTT